Publication:
Shaping the Future of Respiratory Care A Look Into the Next Decade and Strategic Recommendations by the European Forum for Research and Education in Allergy and Airways Diseases
| cris.virtual.department | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtual.orcid | #PLACEHOLDER_PARENT_METADATA_VALUE# | |
| cris.virtualsource.department | 895101a7-1d22-4dbc-ba32-f9546bc915c6 | |
| cris.virtualsource.orcid | 895101a7-1d22-4dbc-ba32-f9546bc915c6 | |
| dc.contributor.author | Bertels, Xander | |
| dc.contributor.author | Scadding, Glenis K. | |
| dc.contributor.author | Backer, Vibeke | |
| dc.contributor.author | Lau, Susanne | |
| dc.contributor.author | Fokkens, Wytske J. | |
| dc.contributor.author | Barnes, Peter J. | |
| dc.contributor.author | Sprekelsen, Manuel Bernal | |
| dc.contributor.author | Bjermer, Leif | |
| dc.contributor.author | Blaiss, Michael | |
| dc.contributor.author | Borzova, Elena | |
| dc.contributor.author | Bruggen, Marie-Charlotte | |
| dc.contributor.author | Brusselle, Guy G. | |
| dc.contributor.author | Cardell, Lars Olaf | |
| dc.contributor.author | Conti, Diego M. | |
| dc.contributor.author | Cornet, Marjolein | |
| dc.contributor.author | De Corso, Eugenio | |
| dc.contributor.author | De Groeve, Bernard | |
| dc.contributor.author | Djukanovic, Ratko | |
| dc.contributor.author | Fox, Adam T. | |
| dc.contributor.author | Gaga, Mina | |
| dc.date.accessioned | 2026-09-07T14:45:44Z | |
| dc.date.available | 2026-09-07T14:45:44Z | |
| dc.date.createdwos | 2026 | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Chronic respiratory diseases (CRDs) remain 1 of the leading causes of preventable morbidity and disability worldwide, affecting up to one-third of the total Western population in 2025. Recognizing the substantial burden of inflammatory airway diseases such as asthma, COPD, chronic rhinosinusitis, and respiratory allergy, the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized the symposium “Shaping the Future of Respiratory Care” in April 2025 in Brussels, Belgium, at the occasion of the 10-year jubilee. Featuring keynote speakers from the World Health Organization and EUFOREA, this initiative had the following aims: (1) promoting dialogue on translating innovations into daily clinical practice; (2) encouraging collaboration between the different stakeholders in the respiratory field; and (3) defining strategic priorities to transform respiratory care and arrest the CRD epidemic over the next decade. The symposium highlighted the importance of moving toward predictive, preventive, and patient-centered medicine, while supporting value-based health care systems to improve long-term patient outcomes. This report summarizes the main insights and strategic directions discussed at the meeting. | |
| dc.description.wosFundingText | Allergy Strategy Group UK. M. G. reports travel support from Menarini. P. G. reports grants from Sanofi and GSK; consulting fees from Lilly, Insmed, and AstraZeneca; honoraria from GSK and Sanofi; and travel support from GSK. C. G. reports honoraria from Danone, Aspen, Viatris, and Inova. J. H. reports consulting fees from Sanofi, Regeneron, GSK, and AstraZeneca. L. G. H. reports grants from MedImmune, Novartis UK, Roche/Genentech, GSK, Amgen, AstraZeneca, Aerocrine, and Vitalograph; honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann-La Roche, GSK, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; travel support from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Napp Pharmaceuticals; and advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann-La Roche, GSK, Novartis, Theravance, Evelo Biosciences, Sanofi, Teva, and Janssen. E. H. reports grants from Chiesi; consulting fees from Chiesi, Almirall, Bosch Healthcare, GSK, Celltrion Healthcare, and Apogee Therapeutics; honoraria from AstraZeneca, Sanofi, GSK, Chiesi, Firma, Gentili, Lofarma, and Orion Pharma; and advisory boards for AstraZeneca, Sanofi, Regeneron, GSK, Celltrion Healthcare, Allergy Therapeutics, and Blueprint Medicines. C. H. reports honoraria from Sanofi, AstraZeneca, and GSK; advisory boards for Sanofi, AstraZeneca, Lilly, GSK, and Medtronic. D. J. reports grants from the National Institute of Allergy and Infectious Diseases, the National Heart, Lung, and Blood Institute, the National Institutes of Health, GSK, and Regeneron; consulting fees from Avillion, AstraZeneca, GSK, Genentech, Regeneron, Sanofi, and OM Pharma; and Data and Safety Monitoring Board for Pfizer. M. J. reports honoraria from Stallergenes Greer, Takeda, ALK, GSK, Novartis, AstraZeneca, Chiesi, Viatris, and Sanofi; and advisory boards for Takeda, AstraZeneca, GSK, Berlin-Chemie Menarini, Viatris, and KalVista. S. L. reports consulting fees from AstraZeneca, Genentech, GSK, Lyra Therapeutics, OptiNose, and Sanofi-Regeneron. V. L. reports consulting fees from GSK and AstraZeneca; and honoraria from Abbott, Novartis, and Sanofi. E. M. reports honoraria from Airsonett, ALK, AstraZeneca, Chiesi, Novartis, and Sanofi; and advisory boards for Airsonett, ALK, AstraZeneca, Chiesi, Novartis, and Sanofi. J. M. reports grants from Viatris/MEDA Pharma and the Noucor/Uriach Group; honoraria from Menarini, GSK, MSD, Mitsubishi-Tanabe, Noucor/Uriach Group, Viatris/MEDA Pharma, AstraZeneca, Sanofi-Genzyme, and Regeneron Pharmaceuticals;r expert testimony for Uriach Group and Sanofi; and advisory boards for Sanofi-Genzyme, AstraZeneca, Regeneron Pharmaceuticals, Almirall, Viatris/MEDA Pharma, Noucor/Uriach Group, GSK, and Lilly. I. P. reports grants from Chiesi; consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GSK, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, RespiVert, Sanofi, Schering-Plough, and Teva Pharmaceuticals; honoraria from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals; and travel support from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Napp Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, and Teva Pharmaceuticals. A. P. reports grants from AstraZeneca, Sanofi-Regeneron, Insmed, and Aretia; and consulting fees from AstraZeneca, Sanofi-Regeneron, Chiesi, GSK, and Eli Lilly. D. P. reports grants from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi-Genzyme, and UK NHS; consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Teva Pharmaceuticals, and Viatris; honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Inside Practice, GSK, Novartis, Medscape, Regeneron Pharmaceuticals, Sanofi-Genzyme, Teva Pharmaceuticals, and Viatris; expert testimony for GSK; travel support from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, and Teva Pharmaceuticals; advisory boards for AstraZeneca, Amgen, Boehringer Ingelheim, Chiesi, Novartis, Regeneron Pharmaceuticals, Sanofi-Genzyme, Teva Pharmaceuticals, and Viatris; stock ownership in Optimum Patient Care Ltd and Observational and Pragmatic Research Institute Pte Ltd. S. Q. reports consulting fees from GSK; honoraria from AstraZeneca, GSK, Chiesi, Allergy Therapeutics, Regeneron, Sanofi, and Gebro; and travel support from AstraZeneca and GSK. D. R. reports honoraria from ALK-Abello, Menarini, and Thermo Fisher; travel support from Chiesi and IPCRG; and a leadership role at IPCRG. S. Scheire reports grants from EUFOREA. S. Schneider reports grants from AstraZeneca, Sanofi, and GSK; honoraria from AstraZeneca, Sanofi, and GSK; expert testimony for GSK; travel support from AstraZeneca, Sanofi, and GSK; and advisory boards for AstraZeneca, Sanofi, and GSK. B. A. S. reports consulting fees from Lyra, Stryker, Neurent, Spirair, and MCP. M. E. W. reports consulting/advisory honoraria from Allakos,r Areteia Therapeutics, Arrowhead Pharmaceutical, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Enveda Therapeutics, Equillium, General Medicines, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, Recludix Pharma, Roche/Genentech, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Verona Pharma, Zura Bio, AstraZeneca, Amgen, Regeneron, GSK, and Sanofi-Genzyme; research support from AstraZeneca, Amgen, Regeneron, GSK, Sanofi-Genzyme, and Upstream Bio; and stock options in Cellergy Pharma Inc, and Upstream Bio. K. F. R. reports consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, and Sanofi-Regeneron; honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, CSL Behring, Sanofi-Regeneron, GSK, Berlin Chemie, and Menarini; advisory boards for AstraZeneca, Boehringer Ingelheim, Sanofi-Regeneron, and CSL Behring; leadership roles at the German Center for Lung Research (DZL) , the German Chest Society (DGP) , and the American Thoracic Society. P. W. H. reports grants from Sanofi-Regeneron, Novartis, GSK, Medtronic, and Viatris; consulting fees from Sanofi-Regeneron, Novartis, GSK, Medtronic, and Viatris; and honoraria from Sanofi-Regeneron, Novartis, GSK, Medtronic, and Viatris. None declared (V. B., L. B., M. S. B., L. O. C., B. D. G., P. G. G., H. J. H., O. J., P. J., E. K., B. N. L., M. Makela, M. McDonald, A. N. G., P. S.-J., P. S.-G., C. M. E. S., P. K. S., Z. S., M. T. A. T., P. H., J. L. C.) . | |
| dc.identifier.doi | 10.1016/j.chest.2025.12.043 | |
| dc.identifier.issn | 0012-3692 | |
| dc.identifier.pmid | MEDLINE:41544956 | |
| dc.identifier.uri | https://imec-publications.be/handle/20.500.12860/60240 | |
| dc.language.iso | eng | |
| dc.provenance.editstepuser | greet.vanhoof@imec.be | |
| dc.publisher | ELSEVIER | |
| dc.source.beginpage | 1641 | |
| dc.source.endpage | 1652 | |
| dc.source.issue | 6 | |
| dc.source.journal | CHEST | |
| dc.source.numberofpages | 12 | |
| dc.source.volume | 169 | |
| dc.subject.keywords | OBSTRUCTIVE PULMONARY-DISEASE | |
| dc.subject.keywords | CHRONIC RHINOSINUSITIS | |
| dc.subject.keywords | BIOLOGICS | |
| dc.subject.keywords | DIAGNOSIS | |
| dc.subject.keywords | OUTCOMES | |
| dc.subject.keywords | HEALTH | |
| dc.subject.keywords | IMPACT | |
| dc.title | Shaping the Future of Respiratory Care A Look Into the Next Decade and Strategic Recommendations by the European Forum for Research and Education in Allergy and Airways Diseases | |
| dc.type | Journal article | |
| dspace.entity.type | Publication | |
| imec.internal.crawledAt | 2026-07-14 | |
| imec.internal.source | crawler | |
| imec.internal.wosCreatedAt | 2026-07-14 | |
| Files | Original bundle
| |
| Publication available in collections: | ||